

APPENDIX A

Eligibility of Drugs for Extended Drug Supply

Maximum Extended Supply	Cancer Drugs Eligible for Extended Supply <i>(*providing conditions in policy are met)</i>		Cancer Drugs <u>NOT</u> Eligible for Extended Supply (beyond 1 cycle or 1 month)
Two (2) Months	afatinib (Giotrif®)	ponatinib (Iclusig®)	cyclophosphamide
	axitinib (Inlyta®)	trametinib (Mekinist®) +/- dabrafenib	etoposide
	capecitabine	vandetanib (Caprelsa®)	fludarabine
	ceritinib (Zykadia®)	vemurafenib (Zelboraf®) +/-cobimetinib	lomustine
	crizotinib (Xalkori®)		melphalan
	dabrafenib (Tafinlar®) +/- trametinib		methotrexate
	erlotinib		mercaptopurine
	everolimus (Afinitor®)		procarbazine
	gefitinib (Iressa®)		regorafenib
	interferon (subcutaneous)		sorafenib
	lapatinib (Tykerb®)		temozolomide
	lenvatinib (Lenvima®)		thioguanine
	olaparib (Lynparza®)		tretinoin
	osimertinib (Tagrisso®)		
	palbociclib (Ibrance®)		
pomalidomide (Pomalyst®)			
Three (3) Months <i>(**restricted to maximum 84 day supply through Health Canada regulated safety programs)</i>	acitretin (Soriatane®)	megestrol acetate	Any drug given intravenously that requires administration within a treatment centre will <u>not</u> be provided or dispensed to patients for reasons of extended absence from the province.
	abiraterone (Zytiga®)	mitotane	
	denosumab (Xgeva®)	pazopanib (Votrient®) for mRCC	
	enzalutamide (Xtandi®)	ruxolitinib (Jakavi®)	
	ibrutinib (Imbruvica®)	sunitinib (Sutent®)	
	idelalisib (Zydelig®)	** vismodegib (Erivedge®)	
	** lenalidomide (Revlimid®)		
	medroxyprogesterone		
Four (4) Months	chlorambucil		
	bosutinib (Bosulif®)		
	dasatinib (Sprycel®)		
	imatinib (advanced GIST)		
	nilotinib (Tasigna®)		
	octreotide LAR		
Six (6) Months	anagrelide	letrozole	
	anastrozole	leuprolide (Eligard® or Lupron®)	
	bicalutamide	tamoxifen	
	cyproterone		
	degarelix (Firmagon®)		
	exemestane		
	flutamide		
	goserelin (Zoladex LA®)		
	hydroxyurea		
	imatinib (adjuvant GIST, CML)		
	lanreotide (Somatuline®)		

Updated APPENDIX A November 5, 2018